Urologix, Inc. ULGX

Company Overview

Urologix, Inc. was a U.S.-based medical device company focused on the development, manufacture, and commercialization of minimally invasive treatments for benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate common in aging men. The company operated within the urology and medical technology industries and was best known for its microwave thermotherapy systems designed to treat lower urinary tract symptoms associated with BPH. Its principal revenue drivers historically included sales of capital equipment, disposable treatment catheters, and related service and support offerings used by urologists and outpatient care providers.

The company’s primary product platform was the Cooled ThermoTherapy system, marketed under brands including Targis System and later Prostatron-related technologies acquired through industry consolidation. Urologix positioned itself as a provider of office-based alternatives to invasive surgical procedures such as transurethral resection of the prostate (TURP), emphasizing reduced recovery times and lower complication risks. Founded in the early 1990s and headquartered in Minnesota, the company evolved through internal product development, commercialization efforts, and acquisitions within the urology device market. Public filings and historical market data indicate that the company experienced prolonged financial and operational challenges prior to ceasing active operations as a publicly traded enterprise. Some historical operational details vary across archived public sources.